136 related articles for article (PubMed ID: 37090576)
1. APOL1 kidney risk variants in glomerular diseases modeled in transgenic mice.
Yoshida T; Latt KZ; Santo BA; Shrivastav S; Zhao Y; Fenaroli P; Chung JY; Hewitt SM; Tutino VM; Sarder P; Rosenberg AZ; Winkler CA; Kopp JB
bioRxiv; 2023 Mar; ():. PubMed ID: 37090576
[No Abstract] [Full Text] [Related]
2. APOL1-G0 protects podocytes in a mouse model of HIV-associated nephropathy.
Bruggeman LA; Wu Z; Luo L; Madhavan S; Drawz PE; Thomas DB; Barisoni L; O'Toole JF; Sedor JR
PLoS One; 2019; 14(10):e0224408. PubMed ID: 31661509
[TBL] [Abstract][Full Text] [Related]
3. HIV-associated nephropathy: experimental models.
Avila-Casado C; Fortoul TI; Chugh SS
Contrib Nephrol; 2011; 169():270-285. PubMed ID: 21252526
[TBL] [Abstract][Full Text] [Related]
4. Recessive, gain-of-function toxicity in an APOL1 BAC transgenic mouse model mirrors human APOL1 kidney disease.
McCarthy GM; Blasio A; Donovan OG; Schaller LB; Bock-Hughes A; Magraner JM; Suh JH; Tattersfield CF; Stillman IE; Shah SS; Zsengeller ZK; Subramanian B; Friedman DJ; Pollak MR
Dis Model Mech; 2021 Aug; 14(8):. PubMed ID: 34350953
[TBL] [Abstract][Full Text] [Related]
5. Transcriptomic Analysis of Human Podocytes
Yoshida T; Latt KZ; Rosenberg AZ; Shrivastav S; Heymann J; Halushka MK; Winkler CA; Kopp JB
Kidney Int Rep; 2023 Jan; 8(1):164-178. PubMed ID: 36644347
[TBL] [Abstract][Full Text] [Related]
6. APOL1 risk variants affect podocyte lipid homeostasis and energy production in focal segmental glomerulosclerosis.
Ge M; Molina J; Ducasa GM; Mallela SK; Varona Santos J; Mitrofanova A; Kim JJ; Liu X; Sloan A; Mendez AJ; Banerjee S; Liu S; Szeto HH; Shin MK; Hoek M; Kopp JB; Fontanesi F; Merscher S; Fornoni A
Hum Mol Genet; 2021 Apr; 30(3-4):182-197. PubMed ID: 33517446
[TBL] [Abstract][Full Text] [Related]
7. Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice.
Beckerman P; Bi-Karchin J; Park AS; Qiu C; Dummer PD; Soomro I; Boustany-Kari CM; Pullen SS; Miner JH; Hu CA; Rohacs T; Inoue K; Ishibe S; Saleem MA; Palmer MB; Cuervo AM; Kopp JB; Susztak K
Nat Med; 2017 Apr; 23(4):429-438. PubMed ID: 28218918
[TBL] [Abstract][Full Text] [Related]
8. APOL1 localization in normal kidney and nondiabetic kidney disease.
Madhavan SM; O'Toole JF; Konieczkowski M; Ganesan S; Bruggeman LA; Sedor JR
J Am Soc Nephrol; 2011 Nov; 22(11):2119-28. PubMed ID: 21997392
[TBL] [Abstract][Full Text] [Related]
9. RNA sequencing of isolated cell populations expressing human APOL1 G2 risk variant reveals molecular correlates of sickle cell nephropathy in zebrafish podocytes.
Bundy JL; Anderson BR; Francescatto L; Garrett ME; Soldano KL; Telen MJ; Davis EE; Ashley-Koch AE
PLoS One; 2019; 14(6):e0217042. PubMed ID: 31158233
[TBL] [Abstract][Full Text] [Related]
10. APOL1 Renal Risk Variants: Fertile Soil for HIV-Associated Nephropathy.
Kopp JB; Heymann J; Winkler CA
Semin Nephrol; 2017 Nov; 37(6):514-519. PubMed ID: 29110758
[TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein L1 (APOL1) cation current in HEK-293 cells and in human podocytes.
Vandorpe DH; Heneghan JF; Waitzman JS; McCarthy GM; Blasio A; Magraner JM; Donovan OG; Schaller LB; Shah SS; Subramanian B; Riella CV; Friedman DJ; Pollak MR; Alper SL
Pflugers Arch; 2023 Mar; 475(3):323-341. PubMed ID: 36449077
[TBL] [Abstract][Full Text] [Related]
12. APOL1 risk variants and the development of HIV-associated nephropathy.
Goyal R; Singhal PC
FEBS J; 2021 Oct; 288(19):5586-5597. PubMed ID: 33340240
[TBL] [Abstract][Full Text] [Related]
13. APOL1-G0 or APOL1-G2 Transgenic Models Develop Preeclampsia but Not Kidney Disease.
Bruggeman LA; Wu Z; Luo L; Madhavan SM; Konieczkowski M; Drawz PE; Thomas DB; Barisoni L; Sedor JR; O'Toole JF
J Am Soc Nephrol; 2016 Dec; 27(12):3600-3610. PubMed ID: 27026370
[TBL] [Abstract][Full Text] [Related]
14. Impact of APOL1 polymorphism and IL-1β priming in the entry and persistence of HIV-1 in human podocytes.
Mikulak J; Oriolo F; Portale F; Tentorio P; Lan X; Saleem MA; Skorecki K; Singhal PC; Mavilio D
Retrovirology; 2016 Sep; 13(1):63. PubMed ID: 27599995
[TBL] [Abstract][Full Text] [Related]
15. APOL1 renal risk variants exacerbate podocyte injury by increasing inflammatory stress.
Wakashin H; Heymann J; Roshanravan H; Daneshpajouhnejad P; Rosenberg A; Shin MK; Hoek M; Kopp JB
BMC Nephrol; 2020 Aug; 21(1):371. PubMed ID: 32854642
[TBL] [Abstract][Full Text] [Related]
16. APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability.
Lan X; Jhaveri A; Cheng K; Wen H; Saleem MA; Mathieson PW; Mikulak J; Aviram S; Malhotra A; Skorecki K; Singhal PC
Am J Physiol Renal Physiol; 2014 Aug; 307(3):F326-36. PubMed ID: 24899058
[TBL] [Abstract][Full Text] [Related]
17. APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy.
Papeta N; Kiryluk K; Patel A; Sterken R; Kacak N; Snyder HJ; Imus PH; Mhatre AN; Lawani AK; Julian BA; Wyatt RJ; Novak J; Wyatt CM; Ross MJ; Winston JA; Klotman ME; Cohen DJ; Appel GB; D'Agati VD; Klotman PE; Gharavi AG
J Am Soc Nephrol; 2011 Nov; 22(11):1991-6. PubMed ID: 21997397
[TBL] [Abstract][Full Text] [Related]
18. Antisense oligonucleotides ameliorate kidney dysfunction in podocyte-specific APOL1 risk variant mice.
Yang YW; Poudel B; Frederick J; Dhillon P; Shrestha R; Ma Z; Wu J; Okamoto K; Kopp JB; Booten SL; Gattis D; Watt AT; Palmer M; Aghajan M; Susztak K
Mol Ther; 2022 Jul; 30(7):2491-2504. PubMed ID: 35450819
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 Nef acts in synergy with APOL1-G1 to induce nephrocyte cell death in a new
Zhu JY; Fu Y; van de Leemput J; Yu Y; Li J; Ray PE; Han Z
bioRxiv; 2024 May; ():. PubMed ID: 38496548
[No Abstract] [Full Text] [Related]
20. Deletion of podocyte STAT3 mitigates the entire spectrum of HIV-1-associated nephropathy.
Gu L; Dai Y; Xu J; Mallipattu S; Kaufman L; Klotman PE; He JC; Chuang PY
AIDS; 2013 Apr; 27(7):1091-8. PubMed ID: 23343908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
